148
Views
14
CrossRef citations to date
0
Altmetric
Original Research

Multimorbidity by Patient and Tumor Factors and Time-to-Surgery Among Colorectal Cancer Patients in Spain: A Population-Based Study

ORCID Icon, , , , ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 31-40 | Published online: 14 Jan 2020

References

  • Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.v68.630207593
  • Berkman LF, Kawachi I. Social Epidemiology. Oxford University Press; 2000.
  • Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105(1):93–103. doi:10.1038/bjc.2011.18921629244
  • Shenoy P, Harugeri A. Elderly patients’ participation in clinical trials. Perspect Clin Res. 2015;6(4):184–189. doi:10.4103/2229-3485.16709926623388
  • Porta MS, Greenland S, Hernán M, Silva I, Last JM, International Epidemiological Association. A Dictionary of Epidemiology. 6th ed. Oxford University Press: Oxford; 2014.
  • Lujic S, Simpson JM, Zwar N, Hosseinzadeh H, Jorm L. Multimorbidity in Australia: comparing estimates derived using administrative data sources and survey data. PLoS One. 2017;12(8):e0183817. doi:10.1371/journal.pone.018381728850593
  • Macleod U, Mitchell E. Comorbidity in general practice. Practitioner. 2005;249(1669):282–284.15832519
  • Macleod U, Mitchell E, Black M, Spence G. Comorbidity and socioeconomic deprivation: an observational study of the prevalence of comorbidity in general practice. Eur J Gen Pract. 2004;10(1):24–26. doi:10.3109/1381478040909422315060478
  • Tinetti ME, Fried TR, Boyd CM. Designing health care for the most common chronic condition–multimorbidity. JAMA. 2012;307(23):2493–2494. doi:10.1001/jama.2012.526522797447
  • Guthrie B, Payne K, Alderson P, McMurdo ME, Mercer SW. Adapting clinical guidelines to take account of multimorbidity. BMJ. 2012;345:e6341.23036829
  • McLean G, Gunn J, Wyke S, et al. The influence of socioeconomic deprivation on multimorbidity at different ages: a cross-sectional study. Br J Gen Pract. 2014;64(624):e440–e447. doi:10.3399/bjgp14X68054524982497
  • Sarfati D, Koczwara B, Jackson C. The impact of comorbidity on cancer and its treatment. CA Cancer J Clin. 2016;66(4):337–350. doi:10.3322/caac.v66.426891458
  • Gurney J, Sarfati D, Stanley J. The impact of patient comorbidity on cancer stage at diagnosis. Br J Cancer. 2015;113(9):1375–1380. doi:10.1038/bjc.2015.35526461060
  • Stairmand J, Signal L, Sarfati D, et al. Consideration of comorbidity in treatment decision making in multidisciplinary cancer team meetings: a systematic review. Ann Oncol. 2015;26(7):1325–1332. doi:10.1093/annonc/mdv02525605751
  • Sogaard M, Thomsen RW, Bossen KS, Sorensen HT, Norgaard M. The impact of comorbidity on cancer survival: a review. Clin Epidemiol. 2013;5(Suppl 1):3–29. doi:10.2147/CLEP.S4715024227920
  • Cauley CE, Panizales MT, Reznor G, et al. Outcomes after emergency abdominal surgery in patients with advanced cancer: opportunities to reduce complications and improve palliative care. J Trauma Acute Care Surg. 2015;79(3):399–406. doi:10.1097/TA.000000000000076426307872
  • Fritz A, Percy C, Jack A, et al. International Classification of Diseases for Oncology. 3rd ed. World Health Organization;2013 Available from:: https://apps.who.int/iris/bitstream/handle/10665/96612/9789241548496_eng.pdf;jsessionid=776A82AD4DD021FDA6E322900F4E0CEF?sequence=1. Accessed 13, 2020.
  • European High Resolution studies. Available from: http://www.hrstudies.eu. Accessed 13, 2020.
  • Shack L, Jordan C, Thomson CS, Mak V, Moller H. Variation in incidence of breast, lung and cervical cancer and malignant melanoma of skin by socioeconomic group in England. BMC Cancer. 2008;8:271. doi:10.1186/1471-2407-8-27118822122
  • Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–655. doi:10.1097/00000421-198212000-000147165009
  • Maringe C, Fowler H, Rachet B, Luque-Fernandez MA. Reproducibility, reliability and validity of population-based administrative health data for the assessment of cancer non-related comorbidities. PLoS One. 2017;12(3):e0172814. doi:10.1371/journal.pone.017281428263996
  • Brusselaers N, Lagergren J. The Charlson Comorbidity Index in Registry-based Research. Methods Inf Med. 2017;56(5):401–406. doi:10.3414/ME17-01-005129582935
  • Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–1474. doi:10.1245/s10434-010-0985-420180029
  • Rothman KJ. Modern Epidemiology. 4th ed. Lippincott Williams & Wilkins; 2016.
  • Network CRUaNCI. Cancer by deprivation in England: Incidence, 1996-2010, Mortality, 1997-2011. 2014 Accessed 9 May, 2019.
  • Mackenbach JP. Genetics and health inequalities: hypotheses and controversies. J Epidemiol Community Health. 2005;59(4):268–273. doi:10.1136/jech.2004.02680715767378
  • Sarfati D, Gurney J, Lim BT, et al. Identifying important comorbidity among cancer populations using administrative data: prevalence and impact on survival. Asia Pac J Clin Oncol. 2013;12:e47–e56.24354451
  • Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14. doi:10.1016/j.diabres.2009.10.00719896746
  • Huang CW, Sun LC, Shih YL, et al. The impact on clinical outcome of high prevalence of diabetes mellitus in Taiwanese patients with colorectal cancer. World J Surg Oncol. 2012;10:76. doi:10.1186/1477-7819-10-7622553992
  • Onitilo AA, Engel JM, Glurich I, Stankowski RV, Williams GM, Doi SA. Diabetes and cancer I: risk, survival, and implications for screening. Cancer Causes Control. 2012;23(6):967–981. doi:10.1007/s10552-012-9972-322552844
  • Larsen MB, Njor S, Ingeholm P, Andersen B. Effectiveness of colorectal cancer screening in detecting earlier-stage disease-a nationwide cohort study in Denmark. Gastroenterology. 2018;155(1):99–106. doi:10.1053/j.gastro.2018.03.06229626451
  • Salas Trejo D, Portillo Villares I, Espinas Pinol JA, et al. Implementation of colorectal cancer screening in Spain: main results 2006-2011. Eur J Cancer Prev. 2017;26(1):17–26. doi:10.1097/CEJ.000000000000023227167150
  • Mandelblatt J, Andrews H, Kao R, Wallace R, Kerner J. The late-stage diagnosis of colorectal cancer: demographic and socioeconomic factors. Am J Public Health. 1996;86(12):1794–1797. doi:10.2105/AJPH.86.12.17949003140
  • White MC, Holman DM, Boehm JE, Peipins LA, Grossman M, Henley SJ. Age and cancer risk: a potentially modifiable relationship. Am J Prev Med. 2014;46(3 Suppl 1):S7–S15. doi:10.1016/j.amepre.2013.10.02924512933
  • Yancik R, Ganz PA, Varricchio CG, Conley B. Perspectives on comorbidity and cancer in older patients: approaches to expand the knowledge base. J Clin Oncol. 2001;19(4):1147–1151. doi:10.1200/JCO.2001.19.4.114711181680
  • Yancik R, Wesley MN, Ries LA, et al. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer. 1998;82(11):2123–2134. doi:10.1002/(SICI)1097-0142(19980601)82:11<2123::AID-CNCR6>3.0.CO;2-W9610691
  • Sun Z, Adam MA, Kim J, Shenoi M, Migaly J, Mantyh CR. Optimal timing to surgery after neoadjuvant chemoradiotherapy for locally advanced rectal cancer. J Am Coll Surg. 2016;222(4):367–374. doi:10.1016/j.jamcollsurg.2015.12.01726897480
  • Shin DW, Cho J, Kim SY, et al. Delay to curative surgery greater than 12 weeks is associated with increased mortality in patients with colorectal and breast cancer but not lung or thyroid cancer. Ann Surg Oncol. 2013;20(8):2468–2476. doi:10.1245/s10434-013-2957-y23529782
  • Flemming JA, Nanji S, Wei X, Webber C, Groome P, Booth CM. Association between the time to surgery and survival among patients with colon cancer: a population-based study. Eur J Surg Oncol. 2017;43(8):1447–1455. doi:10.1016/j.ejso.2017.04.01428528190
  • Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-83558716
  • Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291(20):2441–2447. doi:10.1001/jama.291.20.244115161894
  • Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1). doi:10.1097/00005650-199801000-00004
  • Sarfati D. Review of methods used to measure comorbidity in cancer populations: no gold standard exists. J Clin Epidemiol. 2012;65(9):924–933. doi:10.1016/j.jclinepi.2012.02.01722739245